Loading clinical trials...
Loading clinical trials...
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Crohn's Disease
Conditions
Interventions
Mirikizumab
Mirikizumab
+4 more
Locations
580
United States
University of Alabama-The Kirklin Clinic
Birmingham, Alabama, United States
Digestive Health Specialists
Dothan, Alabama, United States
Lakeview Clinical Research
Guntersville, Alabama, United States
Care Access Research - Tuscaloosa
Tuscaloosa, Alabama, United States
Research Solutions of Arizona
Litchfield Park, Arizona, United States
Central Arizona Medical Associates, PC
Mesa, Arizona, United States
Start Date
July 23, 2019
Primary Completion Date
August 23, 2023
Completion Date
October 2, 2023
Last Updated
December 27, 2024
NCT06226883
NCT07184931
NCT06918808
NCT07383844
NCT07385131
NCT06100289
Lead Sponsor
Eli Lilly and Company
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions